Considerations for Perioperative Opioid Analgesic Stewardship in Australia: A Focus on Tapentadol
Pain Management · 2023
DOI: 10.2217/pmt-2022-0103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pain Management, 2023. Verfasst von Stephanie C Ternel Lebret. Beteiligte Einrichtung: CSL-Seqirus Medical Affairs 655 Elizabeth Street Melbourne Victoria, Australia. Hauptthemen laut MEDLINE: Chronic Pain, Opioid-Related Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL-Seqirus Australia.
Abstract (Originalsprache)
Opioid-related harm remains a serious public health issue in Australia, where there is a strong focus on judicious use of opioids to optimize postoperative patient outcomes. The risks associated with preoperative opioid use (worsened postoperative pain, surgical outcomes, increased length of stay and financial costs) must be balanced with the risks of sub-optimal post-surgical pain management (development of chronic pain, persistent postsurgical opioid use and opioid dependence). In addition to significantly lower rates of gastrointestinal adverse effects (nausea, vomiting, constipation), tapendatol (vs oxycodone) is less likely to cause excessive sedation and opioid-induced ventilatory impairment, may be associated with less withdrawal symptoms of mild to moderate intensity and significantly lower odds of 3-month persistent postoperative opioid use in certain patient populations. Studies included in this review were phase III/meta-analyses, referenced in Australian clinical guidelines and/or published ≤5 years), except for cost-effectiveness analyses, where all known, relevant published analyses were included. Patient harms from medicines related to morphine, which is part of a group of pain-relieving drugs called opioids, is a serious public health issue in Australia, as such, there is a strong focus on the cautious use of these medicines. Using opioids before surgery is associated with risks such as worse pain after surgery and longer hospital stays, however, when pain after surgery is not managed sufficiently, this can result in long-term pain and therefore the need to use these medicines for longer than recommended. Tapentadol is an opioid that has less stomach/gut side effects, causes less sleepiness, is less likely to cause serious breathing impairment, may have less symptoms when stopping the medication and less chance of long-term (more than 3 months) use compared with a more commonly used opioid (oxycodone).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CSL-Seqirus Medical Affairs 655 Elizabeth Street Melbourne Victoria, Australia.
Förderung
- CSL-Seqirus Australia
Zitieren
APA
Ternel Lebret, S. C. (2023). Considerations for Perioperative Opioid Analgesic Stewardship in Australia: A Focus on Tapentadol. Pain Management. https://doi.org/10.2217/pmt-2022-0103
Vancouver
Ternel Lebret SC. Considerations for Perioperative Opioid Analgesic Stewardship in Australia: A Focus on Tapentadol. Pain Management. 2023. doi:10.2217/pmt-2022-0103
BibTeX
@article{TernelLebret2023,
author = {Ternel Lebret, Stephanie C},
title = {Considerations for Perioperative Opioid Analgesic Stewardship in Australia: A Focus on Tapentadol},
journal = {Pain Management},
year = {2023},
doi = {10.2217/pmt-2022-0103}
}
EUVIMED